Analyst: Genmab cancer data is promising compared to rival

According to a Sydbank analyst, Genmab’s lymphoma treatment, epcoritamab, looks ready to take on the competition following the data release from a phase II study on Saturday.

Photo: Tuala Hjarnø / Genmab / PR

On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).

Having taken a closer look at the results, Senior Equity Analyst at Sydbank Søren Løntoft Hansen says Genmab’s drug is well-positioned in relation to a competing candidate, Roche’s glofitamab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs